DATE: December 1, 2020

TO: Rulemaking Interested Persons

FROM: Virginia Niehaus, Rulemaking Coordinator, Commission for Public Health and Director of Regulatory and Legal Affairs, Division of Public Health

RE: Notification of Proposed Permanent Rule Amendment: 10A NCAC 41A .0101

Pursuant to G.S. 150B-21.2, this memorandum serves as the required notice to interested persons that the North Carolina Commission for Public Health (CPH) is proposing to permanently amend Rule 10A NCAC 41A .0101 to include novel coronavirus infections and novel coronavirus infections causing death on the list of reportable diseases and conditions. These additions were previously made under emergency and temporary rulemaking. However, a permanent amendment is needed to ensure that these reporting requirements do not expire from the administrative code. CPH has submitted notice of its intent to amend this rule to the NC Office of Administrative Hearings (OAH).

In accordance with G.S. 150B-21.4, a fiscal note was prepared for the proposed rule and approved by CPH. The proposed changes will have an impact on state funds and local funds as well as a substantial economic impact. The fiscal note was approved by the NC Office of State Budget and Management (OSBM) on October 23, 2020.

The notice of text that was published in today’s edition of the NC Register is attached to this memorandum and may be found on OAH’s website at https://www.oah.nc.gov/documents/nc-register. The text of the proposed rule and fiscal note may be found on the CPH’s website at https://cph.publichealth.nc.gov/.

A public hearing on the rule is scheduled for Friday, December 18, 2020 at 10:00 am. In an abundance of caution and to address protective measures to help prevent the spread of COVID-19, the public hearing will be held by teleconference. You may participate in the public hearing by dialing 919-715-0769 to join the teleconference. No access code is required.

CPH is accepting public comments on the proposed rule and fiscal note from December 1, 2020 to February 1, 2021. You may submit comments by email to cpacomment@lists.ncmail.net or by mail to Virginia Niehaus, Rulemaking Coordinator, Commission for Public Health, 1931 Mail Service Center, Raleigh, NC 27699-1931. Comments will also be accepted at the public hearing. The proposed effective date of this rule is April 1, 2021.

Should you have questions related to this memorandum, the proposed rule, or the fiscal note, please contact Dr. Jean-Marie Maillard, Medical Director, Communicable Disease Branch, Division of Public Health at 919-546-1650.
Attachment

cc:
Dr. Ronald May, Chair, Commission for Public Health
Mr. Mark Benton, Assistant Secretary for Public Health, Division of Public Health
Dr. Zack Moore, Section Chief, Epidemiology, Division of Public Health
Dr. Jean-Marie Maillard, Medical Director, Communicable Disease Branch, Division of Public Health
Ms. Kirsten Leloudis, Program Manager, Regulatory and Legal Affairs, Division of Public Health
Notice is hereby given in accordance with G.S. 150B-21.2 that the Commission for Public Health intends to amend the rule cited as 10A NCAC 41A .0101.

Link to agency website pursuant to G.S. 150B-19.1(c): https://cph.publichealth.nc.gov/

Proposed Effective Date: April 1, 2021

Public Hearing:
Date: December 18, 2020
Time: 10:00 a.m.
Location: This public hearing will be held by teleconference at (919) 715-0769 (no access code).

Reason for Proposed Action: On February 5, 2020, the Commission for Public Health adopted an amendment to 10A NCAC 41A .0101 under emergency procedures and simultaneously proposed to amend 10A NCAC 41A .0101 under temporary procedures to update the communicable diseases and conditions reporting requirements to include novel coronavirus infections. The emergency amendment went into effect on February 17, 2020. The temporary amendment was subsequently amended to also including novel coronavirus infections causing death, adopted on March 24, 2020, and became effective April 24, 2020. The Commission for Public Health is now proposing to adopt a permanent amendment to ensure that these reporting requirements do not expire from the Code.

Comments may be submitted to: Virginia Niehaus, CPH Rulemaking Coordinator, 1931 Mail Service Center, Raleigh, NC 27699-1931; email cphcomment@lists.ncmail.net

Comment period ends: February 1, 2021

Procedure for Subjecting a Proposed Rule to Legislative Review: If an objection is not resolved prior to the adoption of the rule, a person may also submit written objections to the Rules Review Commission after the adoption of the Rule. If the Rules Review Commission receives written and signed objections after the adoption of the Rule in accordance with G.S. 150B-21.3(b2) from 10 or more persons clearly requesting review by the legislature and the Rules Review Commission approves the rule, the rule will become effective as provided in G.S. 150B-21.3(b1). The Commission will receive written objections until 5:00 p.m. on the day following the day the Commission approves the rule. The Commission will receive those objections by mail, delivery service, hand delivery, or facsimile transmission. If you have any further questions concerning the submission of objections to the Commission, please call a Commission staff attorney at 919-431-3000.

Fiscal impact. Does any rule or combination of rules in this notice create an economic impact? Check all that apply.

☒ State funds affected
☒ Local funds affected
☒ Substantial economic impact (>= $1,000,000)
☐ Approved by OSBM
☐ No fiscal note required

CHAPTER 41 - EPIDEMIOLOGY HEALTH

SUBCHAPTER 41A - COMMUNICABLE DISEASE CONTROL

SECTION .0100 - COMMUNICABLE DISEASE CONTROL

10A NCAC 41A .0101 REPORTABLE DISEASES AND CONDITIONS

(a) The following named diseases and conditions are declared to be dangerous to the public health and are hereby made reportable within the time period specified after the disease or condition is reasonably suspected to exist:

1. acquired immune deficiency syndrome (AIDS) - 24 hours;
2. acute flaccid myelitis – 7 days;
3. anaplasmosis – 7 days;
4. anthrax - immediately;
5. arboviral infection, neuroinvasive – 7 days;
6. babesiosis – 7 days;
7. botulism - immediately;
8. brucellosis - 7 days;
9. campylobacter infection - 24 hours;
10. Candida auris - 24 hours;
11. Carbapenem-Resistant Enterobacteriaceae (CRE) – 24 hours;
(12) chancroid - 24 hours;
(13) chikungunya virus infection - 24 hours;
(14) chlamydial infection (laboratory confirmed) - 7 days;
(15) cholera - 24 hours;
(16) Creutzfeldt-Jakob disease - 7 days;
(17) cryptosporidiosis - 24 hours;
(18) cyclosporiasis - 24 hours;
(19) dengue - 7 days;
(20) diphtheria - 24 hours;
(21) Escherichia coli, shiga toxin-producing infection - 24 hours;
(22) ehrlichiosis - 7 days;
(23) foodborne disease, including Clostridium perfringens, staphylococcal, Bacillus cereus, and other and unknown causes - 24 hours;
(24) gonorrhea - 24 hours;
(25) granuloma inguinale - 24 hours;
(26) Haemophilus influenzae, invasive disease - 24 hours;
(27) Hantavirus infection - 7 days;
(28) Hemolytic-uremic syndrome - 24 hours;
(29) Hemorrhagic fever virus infection - immediately;
(30) hepatitis A - 24 hours;
(31) hepatitis B - 24 hours;
(32) hepatitis B carriage - 7 days;
(33) hepatitis C, acute - 7 days;
(34) human immunodeficiency virus (HIV) infection confirmed - 24 hours;
(35) influenza virus infection causing death - 24 hours;
(36) legionellosis - 7 days;
(37) leprosy - 7 days;
(38) leptospirosis - 7 days;
(39) listeriosis - 24 hours;
(40) Lyme disease - 7 days;
(41) Lymphogranuloma venereum - 7 days;
(42) malaria - 7 days;
(43) measles (rubeola) - immediately;
(44) meningitis, pneumococcal - 7 days;
(45) meningococcal disease - 24 hours;
(46) Middle East respiratory syndrome (MERS) - 24 hours;
(47) monkeypox - 24 hours;
(48) mumps - 7 days;
(49) nongonococcal urethritis - 7 days;
(50) novel coronavirus infection causing death - 24 hours;
(51) novel coronavirus infection - immediately;
(52) novel influenza virus infection - immediately;
(53) plague - immediately;
(54) paralytic poliomyelitis - 24 hours;
(55) pelvic inflammatory disease - 7 days;
(56) psittacosis - 7 days;
(57) Q fever - 7 days;
(58) rabies, human - 24 hours;
(59) rubella - 24 hours;
(60) rubella congenital syndrome - 7 days;
(61) salmonellosis - 24 hours;
(62) severe acute respiratory syndrome (SARS) - 24 hours;
(63) shigellosis - 24 hours;
(64) smallpox - immediately;
(65) spotted fever rickettsiosis - 7 days;
(66) Staphylococcus aureus with reduced susceptibility to vancomycin - 24 hours;
(67) streptococcal infection, Group A, invasive disease - 7 days;
(68) syphilis - 24 hours;
(67) tetanus – 7 days;
(68) trichinosis – 7 days;
(69) tuberculosis - 24 hours;
(70) tularemia – immediately;
(71) typhoid - 24 hours;
(72) typhoid carriage (Salmonella typhi) - 7 days;
(73) v. infection (other than cholera) – 24 hours;
(74) whooping cough – 24 hours;
(75) yellow fever – 7 days; and
(76) zika virus – 24 hours.

(b) For purposes of reporting, "confirmed human immunodeficiency virus (HIV) infection" is defined as a positive virus culture, repeatedly reactive EIA antibody test confirmed by western blot or indirect immunofluorescent antibody test, positive nucleic acid detection (NAT) test, or other confirmed testing method approved by the Director of the State Public Health Laboratory conducted on or after February 1, 1990. In selecting additional tests for approval, the Director of the State Public Health Laboratory shall consider whether such tests have been approved by the federal Food and Drug Administration, recommended by the federal Centers for Disease Control and Prevention, and endorsed by the Association of Public Health Laboratories.

(c) In addition to the laboratory reports for Mycobacterium tuberculosis, Neisseria gonorrhoeae, and syphilis specified in G.S. 130A-139, laboratories shall report using electronic laboratory reporting (ELR), secure telecommunication, or paper reports.

(1) Isolation or other specific identification of the following organisms or their products from human clinical specimens:

(A) Anaplasma spp., the causes of anaplasmosis.
(B) Babesia spp., the cause of babesiosis.
(C) Babesia spp., the cause of babesiosis.
(D) Arthropod-borne virus (any type).
(E) Babesia spp., the cause of babesiosis.
(F) Bacillus anthracis, the cause of anthrax.
(G) Bordetella pertussis, the cause of whooping cough (pertussis).
(H) Borrelia burgdorferi, the cause of Lyme disease (confirmed tests).
(I) Brucella spp., the causes of brucellosis.
(J) Campylobacter spp., the causes of campylobacteriosis.
(K) Candida auris.
(L) Carbapenem-Resistant Enterobacteriaceae (CRE).
(M) Chlamydia trachomatis, the cause of genital chlamydial infection, conjunctivitis (adult and newborn) and pneumonia of newborns.
(N) Clostridium botulinum, a cause of botulism.
(O) Clostridium tetani, the cause of tetanus.
(P) Coronavirus, novel human strain.
(Q) Corynebacterium diphtheriae, the cause of diphtheria.
(R) Coxiella burnetii, the cause of Q fever.
(S) Cryptosporidium spp., the cause of human cryptosporidiosis.
(T) Cyclospora cayetanensis, the cause of cyclosporiasis.
(U) Dengue virus.
(V) Ehrlichia spp., the causes of ehrlichiosis.
(W) Shiga toxin-producing Escherichia coli, a cause of hemorrhagic colitis, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura.
(X) Francisella tularensis, the cause of tularemia.
(Y) Hepatitis A virus.
(Z) Hepatitis B virus or any component thereof, such as hepatitis B surface antigen.
(AA) Human Immunodeficiency Virus, the cause of AIDS.
(BB) Legionella spp., the causes of legionellosis.
(CC) Leptospira spp., the causes of leptospirosis.
(DD) Listeria monocytogenes, the cause of listeriosis.
(EE) Measles virus.
(FF) Middle East respiratory syndrome virus.
(GG) Monkeypox.
(HH) Mumps virus.
(II) Mycobacterium leprae, the cause of leprosy.
(JJ) Plasmodium falciparum, P. malariae, P. ovale, and P. vivax, the causes of malaria in humans.
(KK) Poliovirus (any), the cause of poliomyelitis.
Isolation or other specific identification of the following organisms from normally sterile human body sites:

(A) Group A Streptococcus pyogenes (group A streptococci).
(B) Haemophilus influenzae, serotype b.
(C) Neisseria meningitidis, the cause of meningococcal disease.

Positive serologic test results, as specified, for the following infections:

(A) Fourfold or greater changes or equivalent changes in serum antibody titers to:
- (i) Any arthropod-borne virus associated with neuroinvasive disease.
- (ii) Anaplasma spp., the cause of anaplasmosis.
- (iii) Any hantavirus or hemorrhagic fever virus.
- (iv) Chlamydia psittaci, the cause of psittacosis.
- (v) Chikungunya virus.
- (vi) Coxiella burnetii, the cause of Q fever.
- (vii) Dengue virus.
- (viii) Ehrlichia spp., the causes of ehrlichiosis.
- (ix) Measles (rubeola) virus.
- (x) Mumps virus.
- (xi) Rickettsia rickettsii, the cause of Rocky Mountain spotted fever.
- (xii) Rubella virus.
- (xiii) Varicella virus.
- (xiv) Yellow fever virus.

(B) The presence of IgM serum antibodies to:
- (i) Any arthropod-borne virus associated with neuroinvasive disease.
- (ii) Chikungunya virus.
- (iii) Chlamydia psittaci.
- (iv) Dengue virus.
- (v) Hepatitis A virus.
- (vi) Hepatitis B virus core antigen.
- (vii) Mumps virus.
- (viii) Rubella virus.
- (ix) Rubeola (measles) virus.
- (x) Yellow fever virus.

Laboratory results from tests to determine the absolute and relative counts for the T-helper (CD4) subset of lymphocytes and all results from tests to determine HIV viral load.

Identification of CRE from a clinical specimen associated with either infection or colonization, including all susceptibility results and all phenotypic or molecular test results.

(d) Laboratories utilizing electronic laboratory reporting (ELR) shall report in addition to those listed under Paragraph (c) of this Rule:

(1) All positive laboratory results from tests used to diagnosis chronic Hepatitis C Infection, including the following:
- (A) Hepatitis C virus antibody tests (including the test specific signal to cut-off (s/c) ratio);
- (B) Hepatitis C nucleic acid tests;
- (C) Hepatitis C antigen(s) tests; and
- (D) Hepatitis C genotypic tests.

(2) All HIV genotypic test results, including when available:
- (A) The entire nucleotide sequence; or
- (B) The pol region sequence (including all regions: protease (PR)/reverse transcriptase (RT) and integrase (INI) genes, if available).

(3) All test results for Interferon Gamma Release Assays.

(e) For the purposes of reporting, Carbapenem-Resistant Enterobacteriaceae (CRE) are defined as:

(1) Enterobacter spp., E.coli or Klebsiella spp positive for a known carbapenemase resistance mechanism or positive on a phenotypic test for carbapenemase production; or
Enterobacter spp., E. coli or Klebsiella spp resistant to any carbapenem in the absence of carbapenemase resistance mechanism testing or phenotypic testing for carbapenemase production.

History Note: Authority G.S. 130A-134; 130A-135; 130A-139; 130A-141;
Amended Eff. October 1, 1994; February 1, 1990;
Temporary Amendment Eff. July 1, 1997;
Amended Eff. August 1, 1998;
Temporary Amendment Eff. February 13, 2003; October 1, 2002; February 18, 2002; June 1, 2001;
Amended Eff. April 1, 2003;
Temporary Amendment Eff. November 1, 2003; May 16, 2003;
Amended Eff. January 1, 2005; April 1, 2004;
Temporary Amendment Eff. June 1, 2006;
Amended Eff. April 1, 2008; November 1, 2007; October 1, 2006;
Temporary Amendment Eff. January 1, 2010;
Temporary Amendment Expired September 11, 2011;
Amended Eff. July 1, 2013;
Temporary Amendment Eff. December 2, 2014;
Amended Eff. October 1, 2015;
Emergency Amendment Eff. March 1, 2016;
Temporary Amendment Eff. July 1, 2016;
Amended Eff. January 1, 2018; October 1, 2016;
Pursuant to G.S. 150B-21.3A, rule is necessary without substantive public interest Eff. January 9, 2018;
Amended Eff. October 1, 2018;
Emergency Amendment Eff. February 17, 2020;
Temporary Amendment Eff. April 24, 2020;